Results 71 to 80 of about 2,123 (172)

Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 7, Page 1195-1207, July 2026.
In this interim analysis of the OLYMPIA long‐term extension trial, nemolizumab exhibited sustained efficacy and was well tolerated through 100 weeks, with most adverse events being mild/moderate. Patients showed clinically meaningful improvements in core signs and symptoms.
Franz J. Legat, Shawn G. Kwatra, Adam Reich, Serge Boulinguez, Athanasios Tsianakas, Maxwell Sauder, Sebastien Barbarot, Jacek C. Szepietowski, Curdin Conrad, Andrew E. Pink, Elke Weisshaar, Laurent Misery, Martin Metz, Vivian T. Laquer, Raja K. Sivamani, Gil Yosipovitch, Diamant Thaçi, Lone Skov, Xiaoxiao Chen, Aliene Noda, Zarif K. Jabbar‐Lopez, Christophe Piketty, Sonja Ständer   +22 more
wiley   +1 more source

Prurigo Nodularis in a Patient With Primary B‐Cell Immunodeficiency Successfully Treated With Low‐Dose Methotrexate: A Case Report

Clinical Case Reports
Prurigo nodularis is a chronic pruritic condition that leads to a vicious itch‐scratch cycle, which can significantly impair quality of life. Low‐dose methotrexate is an effective option for patients with chronic nodular prurigo not responding to topical
Hamad El Hajj, Dima Jeha, Jennifer Abi Younis, Peter Noun, Maya Habre   +4 more
doaj   +1 more source

Case report: Dupilumab-induced linear psoriasis: a rare presentation

Frontiers in Medicine
A 42 year-old male with prurigo nodularis treated with dupilumab showed a case of linear psoriasis, highlighting the potential of dupilumab to induce immune shift and chimeric gene expression.
Wen Sun, Kexin Wang, Yuekang Ren, Huajie Yuan, Xiaoqing Lang, Shuping Guo, Hongye Liu   +6 more
doaj   +1 more source

Dupilumab for recalcitrant prurigo nodularis: Case report

Revista da Sociedade Portuguesa de Dermatologia e Venereologia, 2022
Dupilumab is a recombinant fully human monoclonal antibody modulating the signaling of the interleukin (IL)—4 and IL-13 pathways and has been approved for the treatment of moderate/severe atopic dermatitis.
Joel Reis, Inês Raposo, Manuela Selores
doaj  

Prurigo Nodularis [PDF]

Proceedings of the Royal Society of Medicine, 1950
W P, ELFORD, F P, WEBER
openaire   +2 more sources

Dupilumab‐Induced Psoriasis in a Patient with Bullous Pemphigoid

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Nina Matthes, Julian Kött, Finn Abeck, Inga Hansen‐Abeck, Jana Bertels, Nina Booken, Stefan W. Schneider   +6 more
wiley   +1 more source

Nemolizumab for Pruritus Control in Cutaneous T‐Cell Lymphoma: A Case Series

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Yenny Angela, Ralf Gutzmer, Rudolf Stadler   +2 more
wiley   +1 more source

Model‐informed drug development to support nemolizumab clinical development in adults and adolescents with moderate to severe atopic dermatitis

British Journal of Clinical Pharmacology, Volume 92, Issue 6, Page 1744-1759, June 2026.
Abstract Aims Population pharmacokinetic (popPK) and pharmacokinetic‐pharmacodynamic (PK/PD) models were developed to support clinical development of nemolizumab, a humanized monoclonal antibody targeting the IL‐31 receptor α, in adolescents and adults with moderate‐to‐severe atopic dermatitis (AD).
Floris Fauchet, Anna Largajolli, Petra M. Jauslin, Emilie Schindler, Mourad Hamimed, Wannee Kantasiripitak, Antonio Gonçalves, Eline Van Maanen, Khaled Benkali, Tomohisa Saito, Jonathan I. Silverberg, Andreas Wollenberg, Michael Graeber, Liliana Ulianov, Christophe Piketty, Luca Loprete, Vincent Duval, Nathalie Wagner   +17 more
wiley   +1 more source

Reproxalap ‐ A Novel Treatment Option for Allergic Conjunctivitis – A Comprehensive Narrative Review

Health Science Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background and Aims Allergic conjunctivitis is a prevalent, immune‐mediated hypersensitivity disorder of the ocular surface affecting 10%–20% of the global population. Current therapeutic options, while effective to some extent, are often limited by side effects and inconsistent efficacy.
Sanila Mughal, Roshanay Ejaz Awan, Hur Abbas, Zahra Sania, Ashna Habib, Syeda Kaneez Sakina, Amina Mahmud, Mohammed Mahmmoud Fadelallah Eljack   +7 more
wiley   +1 more source

Immunotherapy‐Related Cutaneous Toxicities in Melanoma: A Dermoscopic Perspective

JEADV Clinical Practice, Volume 5, Issue 2, Page 402-414, June 2026.
Dermoscopy serves as a valuable tool in the everyday dermatological and oncological practice for melanoma patients, allowing for the prompt identification of immune‐related cutaneous toxicities and guiding clinicians toward appropriate therapeutic decisions.
Grażyna Kamińska‐Winciorek, Iris Zalaudek, Karolina Zarańska, Bożena Cybulska‐Stopa   +3 more
wiley   +1 more source